Ask AI
Therapeutic Advancements in LS SCLC

CE / CME

Enhancing Outcomes in Limited-Stage Small-Cell Lung Cancer With Recent Therapeutic Advancements 

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Pharmacists: 0.25 contact hour (0.025 CEUs)

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: September 18, 2025

Expiration: March 17, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Mark A. Socinski, MD, provides an overview of recent clinical evidence that marks a paradigm shift in the management of LS-SCLC with a focus on the addition of consolidation immunotherapy in CRT schemes.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

A 62-year-old woman (Eastern Cooperative Oncology Group performance status [PS] 1) presents with chest pain and shortness of breath. Chest x-ray shows a right hilar mass. Chest CT demonstrates a 3.4-cm right upper lobe mass with a 3-cm right hilar lymph node. PET/CT is positive only in the right upper lobe and right hilum. Brain MRI is negative. Endobronchial ultrasound–guided biopsy confirms small-cell lung cancer (SCLC) from the right upper lobe mass and a subcarinal node, consistent with limited-stage (LS) SCLC. She receives concurrent chemoradiation therapy (CRT) with cisplatin/etoposide and once-daily thoracic radiotherapy (RT) to 70 Gy, achieving a good partial response without significant toxicity.

What would you recommend next in this patient’s treatment plan?

How many patients with SCLC do you provide care for in a typical month?